277299-70-4 Usage
Description
2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one is a chemical compound that is identified as an impurity in Eltrombopag (E508000), a medication that acts as an agonist of the Thrombopoietin (Tpo) receptor. 2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one is characterized by its molecular structure, which includes a pyrazolone core with specific substituents that contribute to its properties and potential applications.
Uses
Used in Pharmaceutical Industry:
2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one is used as an impurity in the drug Eltrombopag, which is an agonist of the Thrombopoietin (Tpo) receptor. The application reason for this compound is that it is a byproduct in the synthesis of Eltrombopag, which is utilized for the treatment of thrombocytopenia, a condition characterized by a low platelet count in the blood.
In the context of its pharmaceutical use, it is important to monitor and control the levels of this impurity to ensure the safety and efficacy of the medication. The compound may also be of interest for further research to understand its potential effects on the drug's action and to develop methods for its removal or reduction during the manufacturing process.
Check Digit Verification of cas no
The CAS Registry Mumber 277299-70-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,7,2,9 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 277299-70:
(8*2)+(7*7)+(6*7)+(5*2)+(4*9)+(3*9)+(2*7)+(1*0)=194
194 % 10 = 4
So 277299-70-4 is a valid CAS Registry Number.
277299-70-4Relevant articles and documents
CRYSTALLINE FORM OF ELTROMBOPAG FREE ACID
-
Page/Page column 13, (2016/05/02)
The present invention relates to crystalline form of Eltrombopag free acid and its process for preparation.
Thrombopoietin mimetics
-
Page 17, (2008/06/13)
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.